Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Galapagos's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GXE's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GXE exceeded the German Biotechs industry which returned -10.6% over the past year.
Return vs Market: GXE exceeded the German Market which returned -20.4% over the past year.
Price Volatility Vs. Market
How volatile is Galapagos's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Galapagos undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GXE (€169.95) is trading below our estimate of fair value (€465.32)
Significantly Below Fair Value: GXE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GXE is poor value based on its PE Ratio (66.7x) compared to the Biotechs industry average (39.4x).
PE vs Market: GXE is poor value based on its PE Ratio (66.7x) compared to the German market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: GXE is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: GXE is overvalued based on its PB Ratio (3.9x) compared to the DE Biotechs industry average (3.5x).
How is Galapagos forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GXE's forecast earnings growth (15.5% per year) is above the savings rate (-0.4%).
Earnings vs Market: GXE's earnings (15.5% per year) are forecast to grow faster than the German market (14.3% per year).
High Growth Earnings: GXE's earnings are forecast to grow, but not significantly.
Revenue vs Market: GXE's revenue (9.8% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: GXE's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GXE's Return on Equity is forecast to be low in 3 years time (3.8%).
How has Galapagos performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GXE has a large one-off loss of €179.4M impacting its December 31 2019 financial results.
Growing Profit Margin: GXE became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GXE has become profitable over the past 5 years, growing earnings by 29.8% per year.
Accelerating Growth: GXE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GXE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: GXE's Return on Equity (5.2%) is considered low.
How is Galapagos's financial position?
Financial Position Analysis
Short Term Liabilities: GXE's short term assets (€5.9B) exceed its short term liabilities (€571.8M).
Long Term Liabilities: GXE's short term assets (€5.9B) exceed its long term liabilities (€2.6B).
Debt to Equity History and Analysis
Debt Level: GXE is debt free.
Reducing Debt: GXE had no debt 5 years ago.
Inventory Level: GXE has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if GXE's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GXE is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: GXE is profitable, therefore cash runway is not a concern.
What is Galapagos's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GXE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GXE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GXE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GXE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GXE's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Onno van de Stolpe (60yo)
Mr. Onno van de Stolpe co-founded Galapagos NV in 1999 and has been Chief Executive Officer and Managing Director since 1999. Mr. van de Stolpe served as the Managing Director Genomics at IntroGene BV. He ...
CEO Compensation Analysis
Compensation vs Market: Onno's total compensation ($USD1.62M) is below average for companies of similar size in the German market ($USD5.21M).
Compensation vs Earnings: Onno's compensation has been consistent with company performance over the past year.
|CFO & COO||5.33yrs||no data||0.015% €1.7m|
|Chief Scientific Officer||8.25yrs||no data||0.066% €7.5m|
|Vice President of Investor Relations||no data||no data||no data|
|Senior Director of Communications & Public Affairs||no data||no data||no data|
|Chief Business Officer||2.58yrs||no data||0.034% €3.9m|
|Managing Director of Argenta||6.67yrs||no data||no data|
|Chief Medical Officer||3.08yrs||no data||no data|
|Head of Development||no data||no data||no data|
|Head of Development||no data||no data||no data|
Experienced Management: GXE's management team is seasoned and experienced (6 years average tenure).
|Non-Executive Chairman||16.25yrs||€90.00k||0.023% €2.6m|
|Independent Non-Executive Director||7.08yrs||€45.00k||no data|
|Independent Non-Executive Director||3.75yrs||€43.75k||no data|
|Independent Non-Executive Director||9.58yrs||€52.50k||no data|
|Non-Independent Director||0.50yr||no data||no data|
|Non-Independent Director||0.50yr||no data||no data|
|Director||1yr||no data||no data|
Experienced Board: GXE's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.
Galapagos NV's company bio, employee growth, exchange listings and data sources
- Name: Galapagos NV
- Ticker: GXE
- Exchange: DB
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €11.246b
- Shares outstanding: 64.82m
- Website: https://www.glpg.com
Number of Employees
- Galapagos NV
- Generaal De Wittelaan L11 A3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GLPG||ENXTAM (Euronext Amsterdam)||Yes||Ordinary Shares||NL||EUR||May 2005|
|GXE||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 2005|
|0JXZ||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||May 2005|
|GLPG.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 2005|
|GLPGA||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||May 2005|
|GLPG||WBAG (Wiener Boerse AG)||Yes||Ordinary Shares||AT||EUR||May 2005|
|GXE||ETLX (Eurotlx)||Yes||Ordinary Shares||IT||EUR||May 2005|
|GLPG||NasdaqGS (Nasdaq Global Select)||SPON ADR REPR 1 ORD SHS||US||USD||May 2008|
|GXEA||DB (Deutsche Boerse AG)||SPON ADR REPR 1 ORD SHS||DE||EUR||May 2008|
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company’s clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, and ulcerative colitis; Phase II trials for small bowel CD, fistulizing CD, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. Its clinical stage programs also comprise GLPG1690I, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof of concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, the company engages in the development of GLPG1972, which is in the ROCCELLA Phase II trial in osteoarthritis patients; MOR106 that is in Phase I and II trials in atopic dermatitis patients; and GLPG3312, a Toledo molecule, which is in Phase I clinical development for various indications. Galapagos NV has collaboration agreement with Servier for GLPG1972; Les Laboratoires Servier for GLPG1972; MorphoSys AG and Novartis Pharma AG for MOR106; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis; and Evotec for fibrosis, as well as a drug discovery research collaboration agreement with HitGen to identify small molecule leads. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 22:38|
|End of Day Share Price||2020/04/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.